Background HPV is related to a number of cancer types, causing a considerable burden in
both genders in Europe. Female vaccination programs can substantially reduce the …

Background Infection with HPV 16 and 18, the major causative agents of cervical cancer,
can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines …

Background Introduction of human papillomavirus (HPV) vaccination in settings with the
highest burden of HPV is not universal, partly because of the absence of quantitative …

Objectives China suffers from high burdens of human papillomavirus (HPV) and cervical
cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV …

Cost-effectiveness analysis (CEA) is a well-known, but resource intensive, method for
comparing the costs and health outcomes of health interventions. To build on available …

Background Human papillomavirus (HPV) vaccines are widely available and there have
been studies exploring their potential clinical impact and cost-effectiveness. However, few …

Phase III trials have demonstrated the efficacy of human papillomavirus (HPV) vaccines in
preventing transient and persistent high-risk (hr) HPV infection and precancerous lesions. A …

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV)
vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV …

The object of our study is to project the impact of a prophylactic vaccine against persistent
human papillomavirus (HPV)‐16/18 infection on age‐specific incidence of invasive cervical …

Human papillomavirus (HPV) vaccine effectiveness may differ between settings. Here we
present the first real‐world effectiveness study of HPV vaccination on high‐grade cervical …